tiprankstipranks
Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring
Company Announcements

Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring

An announcement from Aurinia Pharmaceuticals ( (AUPH) ) is now available.

Don't Miss our Black Friday Offers:

Aurinia Pharmaceuticals reported significant financial growth in Q3 2024, with net product revenue up by 36% year-over-year, driven by increased market penetration of LUPKYNIS. The company is undergoing strategic restructuring to focus on continued LUPKYNIS growth and AUR200 development, expecting annualized savings of over $40 million post-restructuring. With strong cash flow and revenue guidance between $210-$220 million for 2024, Aurinia aims to enhance operational efficiency and accelerate key pipeline products.

See more insights into AUPH stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
TipRanks Canadian Auto-Generated NewsdeskAurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
TipRanks Canadian Auto-Generated NewsdeskAurinia Pharmaceuticals Engages at London Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App